SLC22A12 Antibody

What is SLC22A12 and why is it important in research?

SLC22A12 (also known as URAT1, urate anion exchanger 1, or renal-specific transporter) is a membrane protein encoded by the SLC22A12 gene in humans. It functions as a urate transporter and urate-anion exchanger that regulates uric acid levels in the blood. This integral membrane protein is primarily found in the kidneys, specifically in the proximal tubules, where it mediates the reabsorption of urate by facilitating its exchange against organic anions . SLC22A12 is critical for maintaining blood urate homeostasis, with approximately 90% of filtered urate being reabsorbed into the bloodstream under normal conditions . Research on SLC22A12 is particularly important for understanding disorders of uric acid metabolism, including gout and renal hypouricemia.

What types of SLC22A12 antibodies are available for research applications?

SLC22A12 antibodies are available in several formats for research use:

Researchers should select antibodies based on their specific experimental needs, target species (human, mouse, rat), and application requirements .

How should SLC22A12 antibodies be validated before experimental use?

Proper validation of SLC22A12 antibodies is essential to ensure experimental reliability:

• Positive and negative controls: Use kidney tissue (high SLC22A12 expression) as positive control and tissues known not to express SLC22A12 as negative controls .

• Knockdown/knockout validation: Validate using siRNA knockdown samples (like the validated sequence 5′-TCA CCT GCA TCA CCA TCT A-3′) or knockout models to confirm specificity .

• Orthogonal validation: Compare protein expression with RNA-seq data (enhanced validation method) .

• Western blot validation: Confirm single band of appropriate molecular weight (~60 kDa) .

• Multiple antibody approach: Use antibodies from different sources or against different epitopes to confirm results .

• Immunohistochemical pattern: In kidney sections, proper SLC22A12 antibodies should show specific staining in proximal tubule epithelial cells, particularly at the apical membrane .

What are the optimal experimental conditions for immunohistochemistry with SLC22A12 antibodies?

For optimal IHC results with SLC22A12 antibodies:

• Antigen retrieval: Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) is recommended for formalin-fixed paraffin-embedded tissues .

• Blocking: Use 10% goat serum for 1-2 hours at room temperature to minimize background staining .

• Primary antibody dilution: Typically 1:100 to 1:1000 depending on the specific antibody. Prestige Antibodies recommend 1:500-1:1000 for IHC applications .

• Incubation conditions: Overnight incubation at 4°C generally yields optimal results .

• Detection system: Peroxidase-conjugated secondary antibodies with DAB as chromogen work well for visualization .

• Controls: Always include positive controls (kidney tissue) and negative controls (primary antibody omission) .

• Expected pattern: Correct staining should appear on the apical membrane of proximal tubular cells .

How can I effectively design experiments to study SLC22A12 expression in kidney disease models?

When designing experiments to study SLC22A12 expression in kidney disease:

• Sample selection: Include both diseased and adjacent normal tissues. For renal cell carcinoma studies, match tumor tissue with adjacent non-tumorous tissue for direct comparison .

• Multiple detection methods: Combine qRT-PCR, immunoblotting, and immunohistochemistry for comprehensive analysis. For example, use primer sets that amplify SLC22A12 and normalize to GAPDH as endogenous control using the 2^(-ΔΔCt) method .

• Functional correlation: Correlate expression with clinical parameters such as serum uric acid levels and fractional excretion of uric acid (FE UA) .

• Single-cell analysis: Consider single-cell RNA sequencing to identify specific cell populations expressing SLC22A12, as studies have shown only a small subset of renal cells express the transporter .

• Longitudinal design: When possible, follow disease progression to observe temporal changes in SLC22A12 expression .

• Statistical analysis: Use ROC curves to evaluate SLC22A12 as a potential biomarker, as demonstrated in studies of clear cell renal cell carcinoma (ccRCC) where AUC=0.7258 indicated good diagnostic potential .

What experimental approaches are most effective for studying SLC22A12 function?

To investigate SLC22A12 functional properties:

• Transfection models: Establish overexpression and knockdown models using:

  • Overexpression plasmids for SLC22A12

  • siRNA knockdown (validated sequence: 5′-TCA CCT GCA TCA CCA TCT A-3′)

  • Transfection efficiency should be verified by qRT-PCR and Western blot

• Functional assays:

  • Urate uptake assays using radiolabeled urate

  • Anion exchange assays to measure transport activity

  • Colony formation assays to assess effects on cell proliferation (seed 1×10^3 cells per well)

  • Migration/invasion assays to determine impact on cell motility

• Mutational analysis: Generate site-directed mutants of SLC22A12 (such as the S508N variant) to study structure-function relationships .

• Pharmacological inhibition: Use URAT1 inhibitors like dotinurad or lesinurad as tools to probe function .

• Organoid models: Kidney organoids derived from human iPSCs provide a physiologically relevant system to study SLC22A12 function and regulation .

How can I investigate the regulation of SLC22A12 gene expression?

To study SLC22A12 regulation mechanisms:

• Promoter analysis: Analyze the SLC22A12 promoter region for transcription factor binding sites. The promoter contains conserved estrogen response elements (EREs) that respond to estrogen receptor modulation .

• Luciferase reporter assays: Design constructs with the SLC22A12 promoter driving luciferase expression to measure promoter activity under different conditions .

• Chromatin immunoprecipitation: Identify transcription factors that bind to the SLC22A12 promoter in vivo.

• Small molecule studies: Examine the effects of compounds like 27-hydroxycholesterol (27HC), which has been shown to increase SLC22A12 expression through EREs .

• Inhibitor studies: Use ER antagonists like ICI 182,780 to investigate the role of estrogen receptor signaling in SLC22A12 expression regulation .

• Gene set enrichment analysis (GSEA): Apply GSEA to identify biological pathways associated with SLC22A12 expression changes, as studies have linked SLC22A12 to metabolism, cell cycle, and tumor-related signaling pathways .

What approaches can be used to investigate the role of SLC22A12 variants in disease pathogenesis?

To study SLC22A12 variants in disease:

• Targeted exon sequencing: Perform targeted exon sequencing of SLC22A12 in patient cohorts, as demonstrated in studies of 480 gout cases and 480 controls to identify disease-associated variants .

• Variant pathogenicity prediction:

  • Employ bioinformatics tools such as Varsome, ConSurf, and DynaMut to predict variant effects

  • Assess evolutionary conservation of altered amino acids

  • Calculate stability changes (ΔΔG) to predict destabilizing mutations

• Structural modeling: Develop 3D models to visualize how mutations affect protein structure, particularly transmembrane domains and interaction interfaces .

• Functional characterization:

  • Express variant proteins in heterologous systems

  • Measure urate transport activity compared to wild-type

  • Assess membrane localization by immunofluorescence

• Clinical correlation: Correlate variants with clinical parameters such as serum urate levels, fractional excretion of uric acid, and disease phenotypes .

What are common issues when working with SLC22A12 antibodies and how can they be resolved?

When troubleshooting SLC22A12 antibody experiments:

• High background in IHC/IF:

  • Increase blocking time/concentration (use 10% serum for 2+ hours)

  • Optimize primary antibody dilution (try 1:1000 instead of 1:500)

  • Include 0.1-0.3% Triton X-100 in washing steps

  • Use affinity-purified antibodies with demonstrated specificity

• Weak or no signal in Western blot:

  • Verify protein isolation from membrane fractions (SLC22A12 is an integral membrane protein)

  • Avoid harsh detergents that may destroy the epitope

  • Try reducing SDS-PAGE conditions (12% gel at 90-120 mV for 90 min)

  • Optimize transfer conditions (300 mA for 60 min to PVDF membrane)

• Non-specific bands:

  • Use peptide competition assays to confirm specificity

  • Try alternative antibodies targeting different epitopes

  • Include positive control (kidney tissue) and negative control tissues

• Inconsistent results:

  • Standardize tissue processing and fixation protocols

  • Maintain consistent antibody incubation times and temperatures

  • Use automated systems when possible to reduce variability

How should conflicting data regarding SLC22A12 expression or function be interpreted?

When faced with conflicting SLC22A12 data:

• Antibody specificity: Determine if different antibodies targeting different epitopes were used, which could explain discrepancies in expression patterns .

• Technical differences: Evaluate methodological variations such as fixation protocols, antigen retrieval methods, or detection systems that might affect results.

• Tissue heterogeneity: Consider that SLC22A12 expression is limited to specific cell populations. Single-cell studies show that only a small number of cells express SLC22A12, which might explain inconsistencies in bulk tissue analyses .

• Physiological regulation: SLC22A12 expression can be regulated by hormones and metabolic conditions, so differences in experimental conditions might influence results .

• Isoform-specific detection: Two transcript variants encoding different SLC22A12 isoforms exist ; determine if assays are detecting specific or all isoforms.

• Cross-species differences: Although conserved, SLC22A12 has species-specific differences in regulation and function; ensure proper species-matched controls are used .

• Disease context: In pathological states such as ccRCC, SLC22A12 expression is downregulated , so conflicting results might reflect different disease stages or heterogeneity.

How can SLC22A12 antibodies be applied in cancer research beyond traditional expression studies?

Advanced applications of SLC22A12 antibodies in cancer research:

• Prognostic biomarker development: SLC22A12 shows potential as a prognostic and diagnostic biomarker for ccRCC, with low expression correlating with poor prognosis. Further validation using tissue microarrays and large patient cohorts could establish clinical utility .

• Signaling pathway interaction: SLC22A12 affects tumor cell properties through the PI3K/Akt pathway. Using antibodies to simultaneously detect SLC22A12, PI3K, p-PI3K, AKT1, and p-AKT1 can elucidate these regulatory mechanisms .

• Therapeutic target assessment: As URAT1 inhibitors already exist for gout therapy, research could investigate their potential repurposing for cancers with altered SLC22A12 expression.

• Metabolic profiling: Combine SLC22A12 expression analysis with metabolomics to understand how its transport function affects tumor cell metabolism.

• Immune microenvironment studies: Investigate correlations between SLC22A12 expression and immune cell infiltration, as uric acid can act as a danger signal in the tumor microenvironment.

What are current approaches to studying the relationship between SLC22A12 polymorphisms and metabolic disorders?

Current methodologies for studying SLC22A12 in metabolic disorders:

• Integrated genetic-metabolic analysis: Combine genotyping of SLC22A12 variants (like rs11602903) with metabolic phenotyping to establish connections with obesity and metabolic syndrome .

• Multiple variant analysis: Apply the "Common Disease, Multiple Common and Rare Variant" model to understand how both common and rare SLC22A12 variants collectively influence disease risk .

• Epistatic interaction studies: Investigate interactions between SLC22A12 and other genes like ABCG2, as research suggests the anti-gout effect of URAT1 dysfunction can outweigh the gout-promoting effect of ABCG2 variants .

• Hormonal regulation research: Study how estrogen receptor modulators like 27HC affect SLC22A12 expression and function, particularly in sex-specific metabolic disorders .

• Mouse models with altered Cyp7b1: Utilize Cyp7b1-knockout mice that have elevated 27HC levels to study the in vivo effects on SLC22A12 expression and uric acid handling .

• Fractional excretion measurements: Calculate fractional excretion of uric acid [FE UA = (U_UA × S_Cr)/(S_UA × U_Cr) × 100] to assess the functional impact of SLC22A12 variants on renal handling of urate .